Welcome to our dedicated page for Biomind Labs news (Ticker: BMNDF), a resource for investors and traders seeking the latest updates and insights on Biomind Labs stock.
Biomind Labs Inc. (BMNDF) is a biotechnology innovator developing advanced therapies for neurological and psychiatric disorders through novel drug delivery systems. This page provides investors and industry observers with timely updates on clinical trials, regulatory milestones, and research developments critical to understanding the company's progress.
Access comprehensive collection of official press releases and curated news covering BMNDF's preclinical studies, strategic partnerships, and advancements in treating conditions linked to neuroinflammation. Resources are organized to highlight material events including Phase II trial initiations, intellectual property updates, and nanotechnology innovations enhancing treatment efficacy.
Key updates include progress on tryptamine-based formulations, metabolic disorder research intersecting with neurological pathways, and collaborations advancing psychedelic-derived therapies. All content is maintained to reflect BMNDF's commitment to rigorous scientific validation and regulatory compliance.
Bookmark this page for streamlined access to verified updates about Biomind Labs' pioneering work in biopharmaceutical development. Check regularly for new insights into their pipeline candidates and emerging treatment paradigms.
Biomind Labs (OTC:BMNDF) announced on December 3, 2025 that it is advancing its 5‑MeO‑DMT candidate BMND08 into FDA-directed commercial development using a newly engineered proprietary nano‑formulation.
The company reported a Phase 2 signal described as a 100% response rate in Alzheimer's-related mood disorders, said third‑party patent observations were successfully resolved and that the patent application remains in good standing. Biomind is preparing regulatory and technical material for FDA discussion, including pivotal trial design and possible expedited pathways such as Breakthrough Therapy.
The company also granted 6,200,000 incentive stock options at an exercise price of $0.35 expiring November 3, 2030.
Biomind Labs (OTC:BMNDF) announced that the Ontario Securities Commission revoked its cease trade order issued April 4, 2025, effective November 25, 2025, after the company filed required continuous disclosure documents.
The company filed annual audited financial statements, MD&A, officers' certificates for year ended December 31, 2024, interim financials for March 31, June 30 and September 30, 2025, the annual information form for 2024, and Form 51-102F6; all are available on SEDAR+.
The company noted continuing financial constraints, a going concern uncertainty due to ongoing operating losses and the need for additional financing, and said it will hold an annual general and special meeting before February 25, 2026.
Biomind Labs (OTC:BMNDF) filed multiple amended and interim continuous disclosure documents on SEDAR+ on November 18, 2025, including amended MD&A and officers' certificates for year ended Dec 31, 2024 and interim unaudited financials and MD&A for periods through Sep 30, 2025.
The amended MD&A were prepared after a corrective disclosure request from Ontario Securities Commission staff and include enhanced disclosure on business operations, drug candidate programs, period‑over‑period variance explanations, and added audit committee and corporate governance disclosure for 2024.
The company confirmed it remains subject to a cease trade order issued by the Commission on Apr 4, 2025 for earlier failures to file audited 2024 financials; the newly filed documents are now available on SEDAR+.
The board appointed Scott Ackerman as an independent director and Audit Committee member; he is CEO of Emprise Capital and has two decades of restructuring and audit committee experience.
Biomind Labs responds positively to U.S. government's progressive stance on psychedelic therapies, marked by the nomination of a new Health Secretary supportive of innovative mental health solutions. The company's drug candidate BMND08 showed 100% efficacy in Phase II trials, achieving remission from depression, anxiety, and stress by week 5. The company plans to pursue Breakthrough Therapy Designation with the FDA. Biomind's portfolio includes several drug candidates: Triptax™ (FDA IND clearance), BMND01 (DMT), BMND07 (5-MeO-DMT), BMND02 (nasal), and BMND08 (sublingual formulation).
Biomind Labs Inc. (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI) has announced plans to advance a new Phase II clinical trial for its proprietary compound BMND06, targeting obesity treatment through neurological pathways. Key findings from pre-clinical studies include:
1. BMND06 is physiologically safe with low toxicity and no mutagenic effects.
2. It significantly reduces LPS-induced IL-6 levels in colon cancer cell lines, outperforming dexamethasone by fivefold.
3. The compound shows potential in treating obesity as a neurological condition, addressing the global obesity epidemic affecting 2.3 billion people worldwide.
CEO Alejandro Antalich emphasized BMND06's potential to redefine obesity treatment by targeting neuroinflammation and neural pathways regulating metabolism and energy balance.
Biomind Labs has initiated a Phase II clinical trial for its BMND08 candidate, a sublingual formulation of 5-MeO-DMT, targeting anxiety and depression in Alzheimer’s disease. Led by Dr. Martín Bruno and involving 40 participants aged 50-75, the trial aims to assess the association of these symptoms with Amnestic Mild Cognitive Impairment, which could predict progression to Alzheimer’s. The trial highlights the increasing global burden of dementia, anticipated to reach 139 million by 2050, emphasizing the urgent need for effective treatments. Biomind Labs focuses on innovative therapies for neurological disorders, aiming to provide affordable treatment options.
FAQ
What is the current stock price of Biomind Labs (BMNDF)?
What is the market cap of Biomind Labs (BMNDF)?
